698 related articles for article (PubMed ID: 30665488)
1. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract][Full Text] [Related]
4. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
5. Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.
Bastholt L; Schmidt H; Bjerregaard JK; Herrstedt J; Svane IM
Eur J Cancer; 2019 Sep; 119():122-131. PubMed ID: 31442816
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Marabelle A; Le DT; Ascierto PA; Di Giacomo AM; De Jesus-Acosta A; Delord JP; Geva R; Gottfried M; Penel N; Hansen AR; Piha-Paul SA; Doi T; Gao B; Chung HC; Lopez-Martin J; Bang YJ; Frommer RS; Shah M; Ghori R; Joe AK; Pruitt SK; Diaz LA
J Clin Oncol; 2020 Jan; 38(1):1-10. PubMed ID: 31682550
[TBL] [Abstract][Full Text] [Related]
7. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.
Moya-Plana A; Herrera Gómez RG; Rossoni C; Dercle L; Ammari S; Girault I; Roy S; Scoazec JY; Vagner S; Janot F; Eggermont AMM; Robert C
Cancer Immunol Immunother; 2019 Jul; 68(7):1171-1178. PubMed ID: 31172258
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Zhao P; Li L; Jiang X; Li Q
J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
[TBL] [Abstract][Full Text] [Related]
11. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
12. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
13. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
14. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer.
Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A
Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265
[TBL] [Abstract][Full Text] [Related]
15. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.
Kilickap S; Guven DC; Aktepe OH; Aktas BY; Dizdar O
J Oncol Pharm Pract; 2020 Mar; 26(2):496-499. PubMed ID: 31256744
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G
Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402
[TBL] [Abstract][Full Text] [Related]
17. DNA mismatch repair in cancer.
Baretti M; Le DT
Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
Kluger HM; Chiang V; Mahajan A; Zito CR; Sznol M; Tran T; Weiss SA; Cohen JV; Yu J; Hegde U; Perrotti E; Anderson G; Ralabate A; Kluger Y; Wei W; Goldberg SB; Jilaveanu LB
J Clin Oncol; 2019 Jan; 37(1):52-60. PubMed ID: 30407895
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.
Ciardiello D; Vitiello PP; Cardone C; Martini G; Troiani T; Martinelli E; Ciardiello F
Cancer Treat Rev; 2019 Jun; 76():22-32. PubMed ID: 31079031
[TBL] [Abstract][Full Text] [Related]
20. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition.
Blake Z; Marks DK; Gartrell RD; Hart T; Horton P; Cheng SK; Taback B; Horst BA; Saenger YM
J Immunother Cancer; 2018 Apr; 6(1):25. PubMed ID: 29622046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
